Payment overview · 2025
General Payments
$930.68
53 reported records · 15 companies
Healthcare provider profile · identity verified
Nirav A Sheth, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BOWLING GREEN, KY · NPI 1134137144
Verified facts
What the public records show
CMS Open Payments records show Nirav A Sheth, MD received $930.68 in general payments during 2025 across 53 reported records.
AstraZeneca Pharmaceuticals LP accounted for 17.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Rexulti, Shingrix, Trelegy Ellipta, Vraylar, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Lokelma by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Trelegy Ellipta by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1299 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $163.31 | 17.6% | 8 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $136.80 | 14.7% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $108.55 | 11.7% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $83.25 | 8.9% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $76.64 | 8.2% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $67.11 | 7.2% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $67.10 | 7.2% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $59.96 | 6.4% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $56.59 | 6.1% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.19 | 2.4% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $20.71 | 2.2% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $18.84 | 2.0% | 1 | 2025 |
| EVOKE PHARMA, INC. | Unresolved — no canonical attribution shown | $18.76 | 2.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.48 | 1.7% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.39 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $930.68 | 53 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $136.80 | 11 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $113.26 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $88.02 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $88.02 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $67.10 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $54.77 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $54.77 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $53.09 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $53.09 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $49.68 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $49.68 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $46.26 | 2 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $22.19 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $20.71 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $20.53 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $19.97 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $18.84 | 1 | 2025 |
Source payment records
|
|||||
| GIMOTI Normalized: gimoti |
Drug | EVOKE PHARMA, INC. | $18.76 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.43 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.48 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.26 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.26 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.26 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $14.22 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $13.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 1299 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 126 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 24 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 108 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
85 | 22 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
57 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
128 | 27 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
126 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
58 | 56 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
24 | 21 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
108 | 29 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1299 | 208 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1960 | 464 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1438 | 274 |
| Furosemide | Furosemide | 1333 | 299 |
| Eliquis | Apixaban | 1299 | 208 |
| Amlodipine Besylate | Amlodipine Besylate | 1205 | 269 |
| Metoprolol Tartrate | Metoprolol Tartrate | 1155 | 264 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1153 | 192 |
| Gabapentin | Gabapentin | 1124 | 185 |
| Pantoprazole Sodium | Pantoprazole Sodium | 968 | 243 |
| Sertraline Hcl | Sertraline Hcl | 904 | 168 |
| Lisinopril | Lisinopril | 879 | 199 |
| Losartan Potassium | Losartan Potassium | 755 | 191 |
| Potassium Chloride | Potassium Chloride | 748 | 205 |
| Buspirone Hcl | Buspirone Hcl | 735 | 156 |
| Omeprazole | Omeprazole | 700 | 166 |
| Trazodone Hcl | Trazodone Hcl | 649 | 150 |
| Metoprolol Succinate | Metoprolol Succinate | 636 | 139 |
| Tamsulosin Hcl | Tamsulosin Hcl | 625 | 155 |
| Metformin Hcl | Metformin Hcl | 550 | 129 |
| Clopidogrel | Clopidogrel Bisulfate | 446 | 95 |
| Hydrochlorothiazide | Hydrochlorothiazide | 417 | 84 |
| Escitalopram Oxalate | Escitalopram Oxalate | 399 | 86 |
| Hydralazine Hcl | Hydralazine Hcl | 394 | 73 |
| Donepezil Hcl | Donepezil Hcl | 393 | 88 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 392 | 91 |
| Simvastatin | Simvastatin | 385 | 79 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 384 | 68 |
| Januvia | Sitagliptin Phosphate | 377 | 49 |
| Mirtazapine | Mirtazapine | 369 | 89 |
| Carvedilol | Carvedilol | 359 | 86 |
| Tramadol Hcl | Tramadol Hcl | 325 | 72 |
| Famotidine | Famotidine | 322 | 75 |
| Montelukast Sodium | Montelukast Sodium | 321 | 72 |
| Lorazepam | Lorazepam | 312 | 51 |
| Duloxetine Hcl | Duloxetine Hcl | 306 | 66 |
| Levetiracetam | Levetiracetam | 302 | 60 |
| Finasteride | Finasteride | 295 | 68 |
| Tizanidine Hcl | Tizanidine Hcl | 290 | 65 |
| Meloxicam | Meloxicam | 288 | 93 |
| Divalproex Sodium | Divalproex Sodium | 281 | 50 |
| Oxycodone Hcl | Oxycodone Hcl | 268 | 47 |
| Quetiapine Fumarate | Quetiapine Fumarate | 265 | 61 |
| Allopurinol | Allopurinol | 257 | 71 |
| Citalopram Hbr | Citalopram Hydrobromide | 247 | 52 |
| Pravastatin Sodium | Pravastatin Sodium | 231 | 47 |
| Ondansetron Odt | Ondansetron | 230 | 92 |
| Ondansetron Hcl | Ondansetron Hcl | 229 | 104 |
| Memantine Hcl | Memantine Hcl | 227 | 50 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 226 | 43 |
| Fluticasone Propionate | Fluticasone Propionate | 221 | 73 |
| Ropinirole Hcl | Ropinirole Hcl | 214 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 203 | 88 |
| Bumetanide | Bumetanide | 198 | 42 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 195 | 64 |
| Ezetimibe | Ezetimibe | 190 | 47 |
| Spironolactone | Spironolactone | 180 | 47 |
| Entresto | Sacubitril/Valsartan | 178 | 36 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 177 | 49 |
| Alprazolam | Alprazolam | 176 | 26 |
| Galantamine Hbr | Galantamine Hbr | 176 | 17 |
| Sucralfate | Sucralfate | 175 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 174 | 32 |
| Diclofenac Sodium | Diclofenac Sodium | 166 | 56 |
| Fluoxetine Hcl | Fluoxetine Hcl | 164 | 33 |
| Jardiance | Empagliflozin | 163 | 36 |
| Prednisone | Prednisone | 157 | 65 |
| Glipizide | Glipizide | 151 | 42 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 148 | 27 |
| Pregabalin | Pregabalin | 146 | 32 |
| Risperidone | Risperidone | 144 | 24 |
| Clonazepam | Clonazepam | 143 | 17 |
| Nystatin | Nystatin | 141 | 73 |
| Olanzapine | Olanzapine | 139 | 28 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 134 | 31 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 133 | 56 |
| Brilinta | Ticagrelor | 128 | 27 |
| Cefuroxime | Cefuroxime Axetil | 128 | 101 |
| Primidone | Primidone | 128 | 25 |
| Amiodarone Hcl | Amiodarone Hcl | 126 | 36 |
| Farxiga | Dapagliflozin Propanediol | 126 | 26 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 123 | 27 |
| Latanoprost | Latanoprost | 121 | 27 |
| Midodrine Hcl | Midodrine Hcl | 117 | 31 |
| Clonidine Hcl | Clonidine Hcl | 115 | 32 |
| Promethazine Hcl | Promethazine Hcl | 114 | 36 |
| Alendronate Sodium | Alendronate Sodium | 109 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 108 | 29 |
| Xarelto | Rivaroxaban | 106 | 20 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 104 | 20 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 103 | 23 |
| Baclofen | Baclofen | 101 | 24 |
| Fenofibrate | Fenofibrate Nanocrystallized | 101 | 23 |
| Aripiprazole | Aripiprazole | 100 | 17 |
| Venlafaxine Hcl | Venlafaxine Hcl | 100 | 21 |
| Meclizine Hcl | Meclizine Hcl | 96 | 41 |
| Warfarin Sodium | Warfarin Sodium | 96 | 23 |
| Nifedipine Er | Nifedipine | 95 | 21 |
| Diazepam | Diazepam | 93 | 15 |
| Azithromycin | Azithromycin | 89 | 71 |
| Naproxen | Naproxen | 88 | 26 |
| Topiramate | Topiramate | 87 | 14 |
| Linzess | Linaclotide | 85 | 22 |
| Oxybutynin Chloride | Oxybutynin Chloride | 85 | 16 |
| Atenolol | Atenolol | 84 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 82 | 23 |
| Ibuprofen | Ibuprofen | 81 | 24 |
| Celecoxib | Celecoxib | 80 | 27 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 77 | 19 |
| Bupropion Xl | Bupropion Hcl | 76 | 19 |
| Fenofibrate | Fenofibrate | 76 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 72 | 52 |
| Amitriptyline Hcl | Amitriptyline Hcl | 71 | 17 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 69 | 30 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 69 | 40 |
| Ozempic | Semaglutide | 69 | 15 |
| Lamotrigine | Lamotrigine | 68 | 16 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 68 | 23 |
| Diltiazem Hcl | Diltiazem Hcl | 67 | 20 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 67 | 22 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 66 | 49 |
| Ibandronate Sodium | Ibandronate Sodium | 66 | 16 |
| Propranolol Hcl | Propranolol Hcl | 66 | 14 |
| Cephalexin | Cephalexin | 65 | 49 |
| Paroxetine Hcl | Paroxetine Hcl | 64 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 62 | 22 |
| Doxycycline Hyclate | Doxycycline Hyclate | 61 | 35 |
| Ceftriaxone | Ceftriaxone Sodium | 59 | 34 |
| Nebivolol Hcl | Nebivolol Hcl | 59 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 58 | 56 |
| Fluconazole | Fluconazole | 58 | 47 |
| Oxcarbazepine | Oxcarbazepine | 58 | suppressed |
| Lacosamide | Lacosamide | 57 | suppressed |
| Synthroid | Levothyroxine Sodium | 57 | 15 |
| Albuterol Sulfate | Albuterol Sulfate | 56 | 27 |
| Myrbetriq | Mirabegron | 56 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 55 | 17 |
| Metoclopramide Hcl | Metoclopramide Hcl | 54 | 12 |
| Nitroglycerin | Nitroglycerin | 54 | 35 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 54 | 12 |
| Insulin Lispro | Insulin Lispro | 53 | 21 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 52 | 12 |
| Tradjenta | Linagliptin | 52 | suppressed |
| Loperamide | Loperamide Hcl | 51 | 38 |
| Metformin Hcl Er | Metformin Hcl | 50 | 12 |
| Sevelamer Carbonate | Sevelamer Carbonate | 50 | suppressed |
| Lactulose | Lactulose | 49 | 27 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 49 | suppressed |
| Mupirocin | Mupirocin | 48 | 27 |
| Glimepiride | Glimepiride | 47 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 46 | 15 |
| Methocarbamol | Methocarbamol | 43 | 26 |
| Ranolazine Er | Ranolazine | 43 | 18 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 42 | 23 |
| Digoxin | Digoxin | 41 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 41 | 29 |
| Clindamycin Hcl | Clindamycin Hcl | 40 | 11 |
| Timolol Maleate | Timolol Maleate | 40 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 39 | suppressed |
| Irbesartan | Irbesartan | 39 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 39 | 17 |
| Glucagon Emergency Kit | Glucagon | 38 | 23 |
| Cilostazol | Cilostazol | 36 | suppressed |
| Lidocaine | Lidocaine | 36 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 36 | 30 |
| Nystop | Nystatin | 36 | 21 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 35 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 35 | suppressed |
| Levofloxacin | Levofloxacin | 35 | 24 |
| Bupropion Hcl | Bupropion Hcl | 34 | suppressed |
| Chlorthalidone | Chlorthalidone | 34 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 33 | 12 |
| Santyl | Collagenase Clostridium Hist. | 33 | 15 |
| Dapagliflozin | Dapagliflozin Propanediol | 32 | 12 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 31 | suppressed |
| Estradiol | Estradiol | 31 | suppressed |
| Ketoconazole | Ketoconazole | 31 | suppressed |
| Ramipril | Ramipril | 31 | suppressed |
| Ssd | Silver Sulfadiazine | 31 | suppressed |
| Valsartan | Valsartan | 31 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 31 | 14 |
| Budesonide | Budesonide | 30 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 30 | suppressed |
| Valproic Acid | Valproic Acid | 30 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 29 | 11 |
| Lokelma | Sodium Zirconium Cyclosilicate | 29 | suppressed |
| Arformoterol Tartrate | Arformoterol Tartrate | 28 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 28 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 28 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 28 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | suppressed |
| Carbamazepine | Carbamazepine | 27 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 27 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 26 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 26 | suppressed |
| Fycompa | Perampanel | 26 | suppressed |
| Humulin R | Insulin Regular, Human | 26 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 25 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 25 | 16 |
| Dorzolamide Hcl | Dorzolamide Hcl | 25 | suppressed |
| Klayesta | Nystatin | 25 | 14 |
| Lidocaine Hcl | Lidocaine Hcl | 25 | 21 |
| Nyamyc | Nystatin | 25 | 20 |
| Silver Sulfadiazine | Silver Sulfadiazine | 25 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 25 | 16 |
| Tresiba Flextouch U-100 | Insulin Degludec | 25 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 24 | suppressed |
| Repatha Sureclick | Evolocumab | 24 | suppressed |
| Restasis | Cyclosporine | 24 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 24 | 21 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 24 | suppressed |
| Invokana | Canagliflozin | 23 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 22 | suppressed |
| Dutasteride | Dutasteride | 22 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | 16 |
| Vascepa | Icosapent Ethyl | 22 | suppressed |
| Xifaxan | Rifaximin | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Cyclosporine | Cyclosporine | 21 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 21 | 12 |
| Humalog | Insulin Lispro | 21 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 21 | suppressed |
| Novolog | Insulin Aspart | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 14 |
| Vraylar | Cariprazine Hcl | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 15 |
| Febuxostat | Febuxostat | 20 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 20 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 19 | suppressed |
| Enulose | Lactulose | 19 | suppressed |
| Eszopiclone | Eszopiclone | 19 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 19 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 19 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 19 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 19 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | 12 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 18 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 17 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 17 | suppressed |
| Calcium Acetate | Calcium Acetate | 16 | suppressed |
| Dulera | Mometasone/Formoterol | 16 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 16 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 16 | suppressed |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Dupixent Pen | Dupilumab | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Alphagan P | Brimonidine Tartrate | 14 | suppressed |
| Asenapine Maleate | Asenapine Maleate | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Clobazam | Clobazam | 14 | suppressed |
| Dexamethasone | Dexamethasone | 14 | suppressed |
| Fluorometholone | Fluorometholone | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | 11 |
| Levalbuterol Hcl | Levalbuterol Hcl | 14 | suppressed |
| Rivastigmine | Rivastigmine | 14 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 14 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 14 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 13 | suppressed |
| Bimatoprost | Bimatoprost | 13 | suppressed |
| Cefadroxil | Cefadroxil | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Etodolac | Etodolac | 13 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Letrozole | Letrozole | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 13 | suppressed |
| Repatha Syringe | Evolocumab | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Tetrabenazine | Tetrabenazine | 13 | suppressed |
| Victoza 3-Pak | Liraglutide | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 12 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 12 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Glucagen | Glucagon | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 11 | 11 |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Pioglitazone-Glimepiride | Pioglitazone Hcl/Glimepiride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $930.68 · 53 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, ACCRUFER, BREZTRI, CAPLYTA, COMIRNATY, ELIQUIS, EVENITY, FANAPT, FARXIGA, GIMOTI, KEVEYIS, Kerendia, Leqembi, NURTEC ODT, OTEZLA, PAXLOVID, PREVNAR 20, QULIPTA, REPATHA, REXULTI, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, VYEPTI, XIFAXAN | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error